Laparoscopic Cryoablation of Uterine Fibroids

Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3™ System in a Percutaneous Laparoscopic-assisted Approach

NCT01735812•IceCure Medical Ltd.

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate the safety \& efficacy of cryoablation using IceCure medical's IceSense3™ device for the treatment of symptomatic uterine fibroids in a percutaneous lap-assisted approach.

Eligibility

Age

30 - 50 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Pre-menopausal woman between the ages of 30 and 50 (inclusive)
•2. Patient had completed her family planning and does not desire future childbearing.
•3. Patient is suffering from menorrhagia as a result of symptomatic uterine fibroids.
•4. Patient's uterus size is smaller than 18 gestational weeks.
•5. Patient wishes to preserve her uterus and avoid hysterectomy.
•6. Patient has 1-3 treatable uterine fibroids in size of up to 10cm measured by US/MRI.
•7. Overall treated fibroid volume is ≤ 3,138cm3 (width x length x height x 0.523)
•8. Patient has clinical menorrhagia as indicated by menstrual blood loss of ≥160 ml during one baseline cycle prior to treatment.
•9. Patient is able to visit the clinic as needed during the 1 year follow-up period following the treatment.
•10. The patient has been informed of the study and agrees to its provisions, and has signed an IRB approved written informed consent, including data privacy authorization.

Exclusion Criteria

•1. Patient had not finished her family planning
•2. Patient was already treated for uterine fibroids in the past (UAE, myomectomy, HIFU,…) or undergone endometrial ablation.
•3. Patient had been treated with GnRH over the last 3 months.
•4. Patient has known symptomatic endometriosis that cannot be completely removed during laparoscopic procedure.
•5. Patient has known or suspected adenomyosis
•6. Patient had any active abdominal/pelvic inflammatory disease.
•7. Patient has known or suspected gynecologic malignancy.
•8. Patient with submucosal fibroids type "zero"
•9. Patient with undiagnosed vaginal bleeding
•10. Patient with blood clotting disorders
+4 more criteria

Locations (1)

Assaf Harofe

Zrifin, Israel

Key Dates

Start Date

December 1, 2012

Primary Completion Date

December 1, 2015

Completion Date

December 1, 2015

Last Updated

June 13, 2022

Conditions

Symptomatic Uterine Fibroids

Interventions

IceSense3 system

DEVICE